Cargando…

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development

Prostate cancer is globally the second most commonly diagnosed cancer type in men. Recent studies suggest that mutations in DNA repair genes are associated with aggressive forms of prostate cancer and castration resistance. Prostate cancer with DNA repair defects may be vulnerable to therapeutic tar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Virtanen, Verneri, Paunu, Kreetta, Ahlskog, Johanna K., Varnai, Reka, Sipeky, Csilla, Sundvall, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723995/ https://www.ncbi.nlm.nih.gov/pubmed/31357527 http://dx.doi.org/10.3390/genes10080565

Ejemplares similares

Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer
por: Virtanen, Verneri, et al.
Publicado: (2023)

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond
por: Hyväkkä, Anniina, et al.
Publicado: (2021)

Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation
por: Varnai, Reka, et al.
Publicado: (2019)

Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view
por: Varnai, Reka, et al.
Publicado: (2019)

Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease
por: Sipeky, Csilla, et al.
Publicado: (2021)

Optimizing the Schedule of PARP Inhibitors in Combination with (177)Lu-DOTATATE: A Dosimetry Rationale
por: Hallqvist, Andreas, et al.
Publicado: (2021)

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Prostate cancer risk prediction using a polygenic risk score
por: Sipeky, Csilla, et al.
Publicado: (2020)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
por: O’Sullivan Coyne, Geraldine, et al.
Publicado: (2017)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)

Prostate cancer and PARP inhibitors: progress and challenges
por: Teyssonneau, Diego, et al.
Publicado: (2021)

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
por: Murthy, Pooja, et al.
Publicado: (2019)

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer
por: Sreekumar, Sreeja, et al.
Publicado: (2023)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
por: Nizialek, Emily, et al.
Publicado: (2020)

Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer
por: Wilkerson, Paul M, et al.
Publicado: (2016)

PARP inhibitors: current status and implications for anticancer therapeutics
por: Usmani, Hadi, et al.
Publicado: (2013)

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
por: Divan, Ali, et al.
Publicado: (2020)

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
por: Teyssonneau, Diego, et al.
Publicado: (2022)

PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
por: Congregado, Belén, et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

ShAn: An easy-to-use tool for interactive and integrated variant annotation
por: Rathinakannan, Venkat Subramaniam, et al.
Publicado: (2020)

PARP inhibition in UV-associated angiosarcoma preclinical models
por: Weidema, Marije E., et al.
Publicado: (2021)

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
por: Bharathy, Narendra, et al.
Publicado: (2019)

The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems
por: Cai, Lisha, et al.
Publicado: (2022)

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
por: McNevin, Ciara S., et al.
Publicado: (2022)

Use of PARP inhibitors in prostate cancer: from specific to broader application
por: Zhang, Zhenting, et al.
Publicado: (2023)

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
por: Illuzzi, Giuditta, et al.
Publicado: (2022)

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
por: Stossel, Chani, et al.
Publicado: (2023)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree
por: Cannon-Albright, Lisa Anne, et al.
Publicado: (2021)

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
por: Cerrato, Aniello, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d8id92a2osgk4qbdof4kakbf6o